NEW YORK, Sept 21 – Genomics and proteomics company Genomic Solutions (Nasdaq: GNSL) said Thursday it expects sales of its proteomics tools and services to comprise a greater proportion of revenues in 2000 than in 1999.

“Proteomics is definitely growing,” said Christine Ethier, vice president of the proteomics business unit at Genomic Solutions. “Proteomics accounted for 15 percent of sales last year and this year it will account for 20-25 percent of revenues.”

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.